Thermo Fisher Molecular Diagnostics: Overview Of Technologies And Applications In Clinical Testing

Thermo Fisher Molecular Diagnostics: Quality, Regulatory, and Validation Considerations

Regulatory oversight in the United States commonly includes CLIA certification managed by CMS, voluntary accreditation such as CAP surveys, and device-level interactions with the U.S. Food and Drug Administration (FDA). Some assays or instruments may have FDA-cleared or -approved claims; others are marketed as research-use-only and require laboratories to develop and validate laboratory-developed tests (LDTs). U.S. clinical laboratories typically follow CLIA requirements for method validation or verification, and CAP checklists may be used to guide quality systems and documentation.

Validation studies for a chosen platform often document analytical sensitivity, specificity, precision, and reportable range. For molecular methods, limit of detection (LOD) studies are commonly performed using serial dilutions of reference material. U.S. laboratories may obtain characterized reference materials from recognized vendors or public resources and often participate in external proficiency testing to benchmark performance. Documentation of validation protocols and results is typically retained as part of the laboratory’s quality management system.

Quality control strategies usually include the use of positive and negative controls, internal amplification controls for PCR assays, and run-level metrics for sequencing such as read depth and base quality scores. Deviations from control acceptance criteria typically trigger documented investigations and corrective actions. Many U.S. laboratories maintain standard operating procedures that define action thresholds and notification pathways for out-of-range QC results.

Traceability and chain-of-custody are important, particularly where legal or public-health reporting obligations exist. Specimen labeling, electronic tracking, and audit logs support traceability from collection to result. In the U.S., laboratories reporting notifiable conditions commonly follow state and CDC reporting guidelines; design of reporting workflows often considers legal requirements, data elements to transmit, and timelines for reporting.